NO933000L - Anvendelse av C1-inaktivator for fremstilling av et legemiddel for profylakse og behandling av bestemte sykdommer - Google Patents

Anvendelse av C1-inaktivator for fremstilling av et legemiddel for profylakse og behandling av bestemte sykdommer

Info

Publication number
NO933000L
NO933000L NO933000A NO933000A NO933000L NO 933000 L NO933000 L NO 933000L NO 933000 A NO933000 A NO 933000A NO 933000 A NO933000 A NO 933000A NO 933000 L NO933000 L NO 933000L
Authority
NO
Norway
Prior art keywords
inactivator
prophylaxis
drug
manufacture
treatment
Prior art date
Application number
NO933000A
Other languages
English (en)
Norwegian (no)
Other versions
NO933000D0 (no
Inventor
Bernd Eisele
Ulrich Delvos
Andreas Jessel
Original Assignee
Behringwerke Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke Ag filed Critical Behringwerke Ag
Publication of NO933000D0 publication Critical patent/NO933000D0/no
Publication of NO933000L publication Critical patent/NO933000L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO933000A 1992-08-24 1993-08-23 Anvendelse av C1-inaktivator for fremstilling av et legemiddel for profylakse og behandling av bestemte sykdommer NO933000L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4227762A DE4227762A1 (de) 1992-08-24 1992-08-24 Verwendung eines Kallikrein-Inhibitors zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie bestimmter Krankheiten

Publications (2)

Publication Number Publication Date
NO933000D0 NO933000D0 (no) 1993-08-23
NO933000L true NO933000L (no) 1994-02-25

Family

ID=6466096

Family Applications (1)

Application Number Title Priority Date Filing Date
NO933000A NO933000L (no) 1992-08-24 1993-08-23 Anvendelse av C1-inaktivator for fremstilling av et legemiddel for profylakse og behandling av bestemte sykdommer

Country Status (9)

Country Link
US (1) US5939389A (ko)
EP (1) EP0586909A3 (ko)
JP (1) JPH06157343A (ko)
KR (1) KR100290753B1 (ko)
AU (1) AU671287B2 (ko)
CA (1) CA2104636C (ko)
DE (2) DE4227762A1 (ko)
IL (1) IL106776A0 (ko)
NO (1) NO933000L (ko)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4227762A1 (de) * 1992-08-24 1994-03-03 Behringwerke Ag Verwendung eines Kallikrein-Inhibitors zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie bestimmter Krankheiten
AU1042597A (en) * 1995-12-18 1997-07-14 Stichting Sanquin Bloedvoorziening Potentiation of complement and coagulation inhibitory properties of c1-inhibitor.
US20040152635A1 (en) * 1998-06-22 2004-08-05 Albrecht Groner Modified C1 esterase inhibitor for blocking the infectiousness of HIV
DE19827750C1 (de) 1998-06-22 1999-07-29 Centeon Pharma Gmbh Verfahren zum Abtrennen von HIV aus einer Flüssigkeit
US7067713B2 (en) 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
PT1252184E (pt) * 2000-01-31 2008-04-15 Pharming Intellectual Pty Bv Inibidor humano c1 produzido no leite de mamíferos transgénicos
AU2006203549B2 (en) * 2000-01-31 2008-10-09 Pharming Intellectual Property B.V. C1 inhibitor produced in the milk of transgenic mammals
HUE052154T2 (hu) 2003-05-16 2021-04-28 Pharming Intellectual Property B V Rövid felezési idejû C1 inhibitor tranziens kezeléshez
EP3028716B1 (en) 2006-10-10 2020-09-16 Regenesance B.V. Complement inhibition for improved nerve regeneration
ES2714999T3 (es) 2011-09-24 2019-05-31 Csl Behring Gmbh Terapia de combinación que usa inmunoglobulina e inhibidor de C1
US9452203B2 (en) 2011-12-22 2016-09-27 Csl Behring Gmbh Use of C1-inhibitor for the treatment of secondary edema of the central nervous system
US10441631B2 (en) 2013-02-28 2019-10-15 Csl Behring Gmbh Therapeutic agent for amniotic fluid embolism
CN105188750A (zh) 2013-03-08 2015-12-23 德国杰特贝林生物制品有限公司 治疗和预防远端缺血-再灌注损伤
KR20160026905A (ko) 2013-06-28 2016-03-09 체에스엘 베링 게엠베하 인자 ｘｉｉ 억제제 및 ｃ1-억제제를 이용한 병용 치료요법
WO2016196070A1 (en) 2015-06-03 2016-12-08 Children's Hospital Medical Center Compositions and methods for treating neonatal biliary atresia
EP3493832A1 (en) 2016-08-05 2019-06-12 CSL Behring GmbH Pharmaceutical formulations of c1 esterase inhibitor
US20190183991A1 (en) 2016-08-23 2019-06-20 Csl Behring Gmbh Method of preventing acute attacks of hereditary angioedema associated with c1 esterase inhibitor deficiency
AU2018334213A1 (en) 2017-09-15 2020-03-26 Cedars-Sinai Medical Center Methods for improving organ function in organ transplant patients
EP4247416A1 (en) 2020-11-20 2023-09-27 CSL Behring GmbH Method for treating antibody-mediated rejection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3228502A1 (de) * 1982-07-30 1984-02-02 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung des c1-inaktivators und seine verwendung
US5271931A (en) * 1988-09-14 1993-12-21 The Scripps Research Institute Methods for increasing C1 inhibitor concentrations using interferon-gamma and/or interleukin-6
US5030578A (en) * 1989-07-10 1991-07-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Process for the purification of C1-inhibitor
EP0512090B2 (en) * 1990-10-16 2006-11-22 Sonoran Desert Chemicals LLC Treatment of inflammation
WO1992022320A1 (en) * 1991-06-14 1992-12-23 Genentech, Inc. C1 inhibitor variants and treating inflammatory response with c1 inhibitor
DE4227735C2 (de) * 1992-08-21 1995-10-12 Leybold Ag Anordnung zum berührungslosen Messen der Dicke von Schichten
DE4227762A1 (de) * 1992-08-24 1994-03-03 Behringwerke Ag Verwendung eines Kallikrein-Inhibitors zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie bestimmter Krankheiten

Also Published As

Publication number Publication date
CA2104636C (en) 2003-11-11
AU4477893A (en) 1994-03-03
KR100290753B1 (ko) 2001-09-17
JPH06157343A (ja) 1994-06-03
DE4227762A1 (de) 1994-03-03
EP0586909A2 (de) 1994-03-16
KR940003564A (ko) 1994-03-12
US5939389A (en) 1999-08-17
EP0586909A3 (de) 1995-04-05
CA2104636A1 (en) 1994-02-25
DE4244735A1 (de) 1994-03-31
IL106776A0 (en) 1993-12-08
NO933000D0 (no) 1993-08-23
AU671287B2 (en) 1996-08-22

Similar Documents

Publication Publication Date Title
NO933000L (no) Anvendelse av C1-inaktivator for fremstilling av et legemiddel for profylakse og behandling av bestemte sykdommer
SE8406538D0 (sv) Novel derivatives of purine
LU90192I2 (fr) Desirudine et ses sels et dérivés pharmaceutiquement acceptables (revasc)
ES2160707T3 (es) Composiciones que comprenden agentes deteriorantes del adn y p53.
ES2036199T3 (es) Procedimiento de obtencion de un preparado farmaceutico administrable a traves de una membrana corporal.
MD1224B2 (en) Application of nucleoside analogues with 1,3-oxathiolan for treatment of hepatitis B
DK0913156T3 (da) Anvendelse af aktiveret protein C til behandling af hyperkoagulationstilstande i forbindelse med sepsis
ATE87214T1 (de) Verwendung katabolischer enzyme zur herstellung eines medikaments zum bekaempfen der erworbenen immunschwaeche (aids) und deren vorstadien (las, arc).
ES8800946A1 (es) Un procedimiento para preparar derivados de guanina
DE69905368D1 (en) Oxydiertes thymosin beta 4
SE8000435L (sv) N-bensylimidazoler med selektivt inhiberande verkan pa tromboxansyntetasenzymet jemte farmaceutiska beredningar innehallande sadana n-bensylimidazoler och sett for deras framstellning
GR3019514T3 (en) Pharmaceutical preparation for the treatment of prolonged coagulation time
DE3372712D1 (en) A tube set intended for extracorporeal treatment of blood and similar perishable liquids
NZ212067A (en) Derivatives of glycerophosphocholine and glycerophosphoethanolamine; preparation and use
ES549776A0 (es) Procedimiento para la preparacion de pirrolo-bencimidazoles
HUP9801924A2 (hu) Nátrium/hidrogén-csere inhibitorokat és szív- és keringési zavarok kezelésére alkalmas hatóanyagokat tartalmazó gyógyszerkészítmény
MX9205568A (es) Composicion farmaceutica que contiene cantidades de 5-amino-1beta-d-ribofuranosil-imidazol-4-carboxamida.
DE3565935D1 (en) Composition for accelerating recovery of function of hematopoietic organs and the use thereof
BG44379A3 (en) Method for preparing of 9- chlor- 1, 5- benzothiazepine derivatives
FI863565A0 (fi) Foerfarande foer framstaellning av nya pyrrobenzimidazoler, pyrrolbenzoxazoler och pyrrolbenztiazoler.
SE7910554L (sv) Disulfidforeningar
MC1930A1 (fr) Produit antiviral
ES8704962A1 (es) Un procedimiento para preparar 1b-d-ribofuranosil, 1-2-4-triazol-3-carboxamida.
MY124071A (en) Treatment of viral disease in swine
GR3006147T3 (ko)

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application